BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

NEWS: BDSI Completes Acquisition of ELYXYB Learn More >
BDSI Products

Marketed Products

BDSI makes innovative therapies available.

BDSI offers a diverse portfolio of solutions for the treatment of chronic pain, acute migraine, and other serious and debilitating chronic conditions.

Pain Management:


BELBUCA® (buprenorphine) is a medication administered to help manage chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is administered using BioErodible MucoAdhesive (BEMA®) technology.

  • Significant respiratory depression
  • Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Hypersensitivity to buprenorphine

For more information on BELBUCA® visit

Medication Guide Full Prescribing Information


Symproic® (naldemedine) is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (eg, weekly) opioid dosage escalation.

  • Patients with known or suspected gastrointestinal obstruction or at increased risk of recurrent obstruction
  • Patients with a history of a hypersensitivity reaction to naldemedine

For more information on Symproic® visit

Medication Guide Full Prescribing Information


ELYXYB Indication and Usage

ELYXYB is indicated in adults for the acute treatment of migraine with or without aura.

Limitations of Use: ELYXYB is not indicated for the preventive treatment of migraine.

Full Prescribing Information
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, 1-800-FDA-1088. Report an Adverse Event

BELBUCA®, BDSI®, and BEMA® are registered trademarks of BioDelivery Sciences International, Inc. All other trademarks and trade names are the property of their respective owners.

Recent BDSI News

January 20, 2022

Total 2021 Net Revenue expected in the range of $165 - $167 million , as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 - $148 million , as compared to previous guidance of $144-$148 million 2021 EBITDA expected to be in the $40 - $45

Read more
December 20, 2021

RALEIGH, N.C. , Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that the U.S.

Read more
November 3, 2021

Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
January 28, 2022BDSI $3.59/ - -1.91%
Data provided by Nasdaq. Minimum 15 minutes delayed.